- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06493669
Study on the Correlation Between Treg Immune Cells on the Muscle Content and Cognitive Functions of the Elderly
July 7, 2024 updated by: Fifth Affiliated Hospital, Sun Yat-Sen University
In order to explore the impact of the level of the elderly Treg immune cells and the effects of different fat distribution and muscle content, the impact of the level of Treg immune cells on cognitive functions is explored.
The correlation between visceral fat content, subcutaneous fat content and cognitive function.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Li Li
- Phone Number: 15818102211
- Email: 850144863@qq.com
Study Locations
-
-
Guangdong
-
Zhuhai, Guangdong, China, 519000
- Recruiting
- The Fifth Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Li shan Li, master
- Phone Number: 86 15818102211
- Email: 850144863@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Cognitive decline patient
Description
Inclusion Criteria:
- aged 40-90 years old
Exclusion Criteria:
- previous diagnosis of dementia (including Alzheimer's disease, Lewy body dementia, Parkinson's disease, or other dementias) were excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function decline
Time Frame: through study completion, an average of 1 year
|
MoCA score <26
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2023
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
July 1, 2024
First Submitted That Met QC Criteria
July 7, 2024
First Posted (Actual)
July 10, 2024
Study Record Updates
Last Update Posted (Actual)
July 10, 2024
Last Update Submitted That Met QC Criteria
July 7, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZDWY.LNBK.007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.